- Home
- RDI vs MRSN Comparison
RDI vs MRSN Comparison
Compare RDI & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- MRSN
- Stock Information
- Founded
- RDI 1937
- MRSN 2001
- Country
- RDI United States
- MRSN United States
- Employees
- RDI N/A
- MRSN N/A
- Industry
- RDI Movies/Entertainment
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- MRSN Health Care
- Exchange
- RDI Nasdaq
- MRSN Nasdaq
- Market Cap
- RDI 35.7M
- MRSN 37.0M
- IPO Year
- RDI N/A
- MRSN 2017
- Fundamental
- Price
- RDI N/A
- MRSN $9.44
- Analyst Decision
- RDI
- MRSN Strong Buy
- Analyst Count
- RDI 0
- MRSN 3
- Target Price
- RDI N/A
- MRSN $33.00
- AVG Volume (30 Days)
- RDI 46.1K
- MRSN 49.0K
- Earning Date
- RDI 11-13-2025
- MRSN 11-12-2025
- Dividend Yield
- RDI N/A
- MRSN N/A
- EPS Growth
- RDI N/A
- MRSN N/A
- EPS
- RDI N/A
- MRSN N/A
- Revenue
- RDI $219,213,000.00
- MRSN $34,769,000.00
- Revenue This Year
- RDI $5.21
- MRSN N/A
- Revenue Next Year
- RDI $11.45
- MRSN N/A
- P/E Ratio
- RDI N/A
- MRSN N/A
- Revenue Growth
- RDI 7.59
- MRSN 16.14
- 52 Week Low
- RDI $1.17
- MRSN $5.21
- 52 Week High
- RDI $1.87
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- RDI N/A
- MRSN 62.93
- Support Level
- RDI N/A
- MRSN $7.85
- Resistance Level
- RDI N/A
- MRSN $8.35
- Average True Range (ATR)
- RDI 0.00
- MRSN 0.37
- MACD
- RDI 0.00
- MRSN 0.00
- Stochastic Oscillator
- RDI 0.00
- MRSN 77.70
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.